Thyrocare Q1 FY27: Revenue Up 24%, PAT Jumps 34%
Thyrocare Technologies, a diagnostic chain that processes over 1,375 medical tests through a network of 44 labs and a franchisee-driven model, reported a strong start to FY27. Consolidated revenue for the June quarter rose 24% year-on-year to ₹240 crore, while net profit climbed 34% to ₹51.33 crore. The growth was powered by a record addition of ~900 franchisees—the highest quarterly addition in three years—and a 26% jump in its core pathology business, even as the company strategically exited loss-making radiology centres to improve profitability.
Pathology Drives Growth, Radiology Turns Profitable
The standalone pathology business, which accounts for the bulk of Thyrocare’s operations, delivered revenue of ₹225.66 crore in Q1 FY27, a 26% increase over the same quarter last year. The growth was broad-based across its two main channels: franchise revenue grew 27% to ₹142.8 crore, while partnerships—which include online aggregators, corporate wellness programmes, and insurers—rose 26% to ₹71 crore. The direct-to-consumer segment, a smaller 5% of pathology revenue, grew 17%.
The radiology segment, which includes the Nuclear Healthcare and Pulse Hi Tech businesses, saw revenue dip 4% to ₹13.48 crore. However, this was a deliberate move. The company stated it had undertaken a "strategic exit from non-profitable centers" . The impact is visible in the segment's profitability: EBITDA jumped 23% to ₹2.65 crore, and profit after tax surged 379% to ₹1.72 crore, aided by lower depreciation charges following the centre closures .
Margins expanded across the board. Consolidated EBITDA margin improved by 226 basis points to 32.2%, while gross margin rose 292 basis points to 74.1% . The company attributed the margin expansion to operating leverage and cost efficiencies.
Franchisee Network Hits a New Peak
A key driver of Thyrocare’s growth has been the consistent expansion of its franchisee network. The quarterly active franchisee count reached a record 11,730 in Q1 FY27, up from 10,831 in the previous quarter and 9,550 a year ago . The addition of approximately 900 franchisees in a single quarter is the highest in three years, reflecting the success of a strategy that has been in the making for several quarters.
In past earnings calls, management had outlined a clear plan to accelerate franchisee additions. A pay-for-performance structure, implemented nearly three years ago, has "led to renewed energy and motivation within our franchisee network to move up volumes and enter higher slabs," MD and CEO Rahul Guha had stated in the Q4 FY26 call . The company also expanded its field and central teams to penetrate deeper into India, particularly Tier 3 cities and beyond. The Q1 FY27 presentation highlights that the company continues to invest in "structured training and capability building initiatives" for its franchise partners .
The franchisee growth is not just about numbers. Revenue per patient has been steadily rising, from ₹335 in Q1 FY25 to ₹404 in Q1 FY27, even as revenue per test has remained relatively flat at around ₹40 . This indicates that patients are opting for more, or more comprehensive, tests. The number of tests per patient increased from 8.4 to 10.2 over the same two-year period .
The ‘Routine to Remarkable’ Push
The increase in tests per patient and revenue per patient aligns with Thyrocare’s strategic push into specialty diagnostics, branded "From Routine to Remarkable." The company has been expanding its test menu to include advanced offerings like genomics, starting with Non-Invasive Prenatal Testing (NIPT), and in-house allergy testing. In Q1 FY27, it added Gut Microbiome and Whole Exome sequencing to its portfolio .
Management has previously indicated that while routine tests realise only ₹30–₹40 per test, a specialty test can command around ₹1,000, with a much higher absolute gross margin . The Q1 FY27 presentation explicitly states that the specialty expansion is designed to "enhance value per patient and build presence in high value growth segments" . The launch of new regional and hybrid labs in Muzaffarpur, Prayagraj, and Kurnool during the quarter is also aimed at improving turnaround times and supporting this wider test menu in new geographies .
Partnerships Remain a Strong Second Engine
The partnership channel, which includes online aggregators like PharmEasy, corporate wellness platforms, and insurers, contributed 31% of pathology revenue in Q1 FY27. Its 26% year-on-year growth to ₹71 crore underscores its role as a vital growth engine alongside the franchise network .
In the Q4 FY26 earnings call, management had noted that while the partnership business is a strong growth driver, the insurance sub-segment is still nascent, having grown at nearly 45% in FY26 from a small base . The company’s strategy is to broaden these collaborations to "enhance reach, improve accessibility and integrate diagnostics within the broader healthcare ecosystem" . The B2B model, where Thyrocare acts as a backend processing partner for healthtech platforms, allows it to capture demand in metro and Tier 1 cities, complementing the franchise network's strength in Tier 2 and 3 towns.
---